FIG 4.

Response of primary pulmonary aspergillosis in persistently neutropenic rabbits to antifungal therapy measured by survival, pulmonary infarct scores, lung weights, and mean pulmonary tissue residual fungal burden (log CFU/g) in untreated controls (UC) and rabbits receiving ibrexafungerp alone or in combination with oral isavuconazole. Values are given as means ± SEMs. For the measure of survival, the values on the y axis are probability of survival. Survival was plotted by Kaplan-Meier analysis. Differences in survival of treatment groups and UC were analyzed by log-rank test. P values are indicated as follows. Survival, ¶, P < 0.05, prolonged survival in SCY2.5+ISA40- and SCY7.5+ISA40-treated rabbits in comparison to that of single therapy with SCY2.5, SCY7.5, or ISA40; £, P < 0.01, prolonged survival of rabbits treated with SCY2.5+ISA40, SCY7.5+ISA40, and ISA40 alone in comparison to that of the UC. Pulmonary infarct scores, ¶, P < 0.01, decreased infarct scores in SCY2.5+ISA40- and SCY7.5+ISA40-treated rabbits in comparison to that of single therapy with SCY2.5, SCY7.5, or ISA40. Lung weights, *, P < 0.05, decreased lung weights in SCY2.5+ISA40- and SCY7.5+ISA40-treated rabbits in comparison to that of single therapy with SCY2.5, SCY7.5, or the UC. Mean pulmonary tissue residual fungal burden, †, P < 0.01, decreased residual fungal burden in SCY2.5+ISA40-, SCY7.5+ISA40-, and ISA40-treated rabbits in comparison to that of single therapy with SCY2.5, SCY7.5, or UC.